文献速递腹部技术与安全CT

MiraLAX与枸橼酸镁在CT结肠成像肠道准备中的比较

Comparison of MiraLAX and magnesium citrate for bowel preparation at CT colonography.
PubMed 文献 · Abdom Radiol (NY) · 2023-08-29

这项回顾性单中心研究纳入398例筛查性CT结肠成像(CTC),比较双倍剂量枸橼酸镁(MgC,n=297)与8.3盎司MiraLAX(n=101)的肠道准备效果。MiraLAX组残留液体量及液体密度均高于MgC组,结肠壁对比剂涂层影响判读的比例也更高(6.9% vs 1.7%,p=0.008),但两组息肉检出率无显著差异(16% vs 12%,p=0.29)。作者认为低渗性MiraLAX可提供与高渗性MgC相当的诊断质量,尤其考虑到患者安全性和耐受性。

要点

  • MiraLAX组残留液体密度1044±274 HU,高于MgC组713±183 HU(p<0.001)。
  • MiraLAX组结肠壁涂层影响判读占6.9%,高于MgC组1.7%(p=0.008)。
  • 两组息肉检出率无显著差异:MiraLAX组16% vs MgC组12%(p=0.29)。

核心结论

  • 低渗性MiraLAX用于CTC肠道准备似乎可提供与高渗性MgC相当的诊断质量,尤其考虑到患者安全性和耐受性。

研究设计与样本

  • 回顾性单中心研究,共纳入398例筛查性CTC,其中297例采用双倍剂量MgC方案(平均年龄61±5.5岁;男142例/女155例),101例采用8.3盎司(相当于238 g PEG)MiraLAX(平均年龄60±9.6岁;男45例/女56例)。

诊断标准与关键数值

  • 残留液体量占总结肠容积百分比:MgC组7.2±4.2% vs MiraLAX组8.7±3.8%(p=0.001);液体密度:MgC组713±183 HU vs MiraLAX组1044±274 HU(p<0.001)。

临床应用与阅片要点

  • 结肠壁涂层负面影响判读见于MgC组1.7% vs MiraLAX组6.9%(p=0.008);息肉检出率MgC组12% vs MiraLAX组16%(p=0.29)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To compare MiraLAX, a hypo-osmotic lavage, and magnesium citrate (MgC), a hyper-osmotic agent for bowel preparation at CTC.

METHODS: 398 total screening CTC studies were included in this retrospective, single institution study. 297 underwent preparation with a double-dose MgC regimen (mean age, 61 ± 5.5 years; 142 male/155 female) and 101 with 8.3 oz (equivalent to 238 g PEG) of MiraLAX (mean age, 60 ± 9.6 years; 45 male/56 female). Oral contrast for tagging purposes was utilized in both regimens. Studies were retrospectively analyzed for residual fluid volume and attenuation by automated analysis, as well for subjective oral contrast coating of the normal colonic wall and polyps. 50 patients underwent successive CTC studies utilizing each agent (mean, 6.1 ± 1.7 years apart), allowing for intra-patient comparison. Chi-squared, Fisher's exact, McNemar, and t-tests were used for data comparison.

RESULTS: Residual fluid volume (as percentage of total colonic volume) and fluid density was 7.2 ± 4.2% and 713 ± 183 HU for the MgC cohort and 8.7 ± 3.8% and 1044 HU ± 274 for the MiraLAX cohort, respectively (p = 0.001 and p < 0.001, respectively). Similar results were observed for the intra-patient cohort. Colonic wall coating negatively influencing interpretation was noted in 1.7% of MgC vs. 6.9% of MiraLAX examinations (p = 0.008). Polyps were detected in 12% of all MgC vs. 16% of all MiraLAX CTCs (p = 0.29).

CONCLUSION: CTC bowel preparation with the hypo-osmotic MiraLAX agent appears to provide acceptable diagnostic quality that is comparable to the hyper-osmotic MgC agent, especially when factoring in patient safety and tolerance.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Zacharias N, Lubner MG, Kim DH, et al. Comparison of MiraLAX and magnesium citrate for bowel preparation at CT colonography. Abdom Radiol (NY). 2023. PMID: 37644134. doi:10.1007/s00261-023-04025-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。